Role of human CYP2B6 in S-mephobarbital N-demethylation

被引：0

作者：

Kobayashi, K

Abe, S

Nakajima, M

Shimada, N

Tani, M

Chiba, K

Yamamoto, T

机构：

[1] Chiba Univ, Fac Pharmaceut Sci, Lab Biochem Pharmacol & Toxicol, Inage Ku, Chiba 2638522, Japan

[2] Showa Univ, Sch Pharmaceut Sci, Dept Clin Pharm, Tokyo 142, Japan

[3] Int Med Ctr Japan, Dept Gen Surg, Div Surg, Tokyo, Japan

来源：

DRUG METABOLISM AND DISPOSITION | 1999年 / 27卷 / 12期

关键词：

D O I：

暂无

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

The role of cytochrome P-450s (CYPs) in S-mephobarbital N-demethylation was investigated by using human liver microsomes and cDNA-expressed CYPs. Among the 10 cDNA-expressed CYPs studied (CYP1A1, CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP2E1, and CYP3A4), only CYP2B6 could catalyze S-mephobarbital N-demethylation. The apparent K-m values of human liver microsomes for S-mephobarbital N-demethylation were close to that of cDNA-expressed CYP2B6 (about 250 mu M). The N-demethylase activity of S-mephobarbital in 10 human liver microsomes was strongly correlated with immunodetectable CYP2B6 levels (r = 0.920, p < .001). Orphenadrine (300 mu M), a CYP2B6 inhibitor, inhibited the N-demethylase activity of S-mephobarbital in human liver microsomes to 29% of control activity. Therefore, it appears that CYP2B6 mainly catalyzes S-mephobarbital N-demethylation in human liver microsomes.

引用

页码：1429 / 1433

页数：5

共 50 条

[31] CYP2B6 and Bupropion's Smoking-Cessation Pharmacology: The Role of Hydroxybupropion
Zhu, A. Z. X.
Cox, L. S.
Nollen, N.
Faseru, B.
Okuyemi, K. S.
Ahluwalia, J. S.
Benowitz, N. L.
Tyndale, R. F.
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2012, 92 (06) : 771 - 777
[32] PharmVar GeneFocus: CYP2B6
Desta, Zeruesenay
El-Boraie, Ahmed
Gong, Li
Somogyi, Andrew A.
Lauschke, Volker M.
Dandara, Collet
Klein, Kathrin
Miller, Neil A.
Klein, Teri E.
Tyndale, Rachel F.
Whirl-Carrillo, Michelle
Gaedigk, Andrea
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2021, 110 (01) : 82 - 97
[33] Effects of the CYP2B6*6 Allele on Catalytic Properties and Inhibition of CYP2B6 In Vitro: Implication for the Mechanism of Reduced Efavirenz Metabolism and Other CYP2B6 Substrates In Vivo
Xu, Cong
Ogburn, Evan T.
Guo, Yingying
Desta, Zeruesenay
DRUG METABOLISM AND DISPOSITION, 2012, 40 (04) : 717 - 725
[34] Effects of CYP3A5, CYP2C19, and CYP2B6 on the clinical efficacy and adverse outcomes of sibutramine therapy: A crucial role for the CYP2B6*6 allele
Hwang, In Cheol
Park, Ji Young
Ahn, Hong Yup
Kim, Kyoung Kon
Suh, Heuy Sun
Ko, Ki Dong
Kim, Kyoung-Ah
CLINICA CHIMICA ACTA, 2014, 428 : 77 - 81
[35] The role of human CYP2B6 polymorphism in the bioactivation of cyclophosphamide using CDNA expressed enzymes
Afsharian, P.
Teredius, Y.
Hidestrand, M.
Ingelman-Sundberg, M.
Hassan, M.
Lundgren, S.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2007, 13 (02) : 70 - 71
[36] Prevalence of CYP2B6 polymorphisms in Argentinians: the role of genetic testing
Scibona, P.
Vazquez, C.
Cajal, A. R.
Argibay, P. F.
Belloso, W. H.
GENETICS AND MOLECULAR RESEARCH, 2015, 14 (04): : 16594 - 16599
[37] Participation of CYP2C8 and CYP3A4 in the N-demethylation of imatinib in human hepatic microsomes
Nebot, Noelia
Crettol, Severine
d'Esposito, Fabrizio
Tattam, Bruce
Hibbs, David E.
Murray, Michael
BRITISH JOURNAL OF PHARMACOLOGY, 2010, 161 (05) : 1059 - 1069
[38] Metamizole is a potent inducer of human CYP2B6 and CYP3A4
Saussele, T.
Burk, O.
Blievernicht, J. K.
Klein, K.
Nussler, A.
Nussler, N.
Eichelbaum, M.
Schwab, M.
Zanger, U. M.
NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 2007, 375 : 106 - 106
[39] CYP3A4 mediates dextropropoxyphene N-demethylation to nordextropropoxyphene:: human in vitro and in vivo studies and lack of CYP2D6 involvement
Somogyi, AA
Menelaou, A
Fullston, SV
XENOBIOTICA, 2004, 34 (10) : 875 - 887
[40] CYP2B6 allelic variants and non-genetic factors influence CYP2B6 enzyme function
Mango, Katalin
Kiss, Adam Ferenc
Fekete, Ferenc
Erdos, Reka
Monostory, Katalin
SCIENTIFIC REPORTS, 2022, 12 (01)

← 1 2 3 4 5 →